Back to search

Article

Analytical Validation of a Circulating Tumor DNA Assay using PhasED-Seq Technology for Detecting Residual Disease in B-Cell Malignancies

2024-08-10

Abstract excerpt

<h4>Background</h4> Circulating tumor DNA (ctDNA) is a non-invasive biomarker that can be used as a tool to detect minimal residual disease (MRD). MRD can provide important prognostic information in diffuse large B-cell lymphomas (DLBCL). Here, we present an MRD assay with an improved detection method for ctDNA, Phased Variant Enrichment and Detection Sequencing (PhasED-Seq) which leverages phased variants (PVs) t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
32626791-0328-5147-a2af-9bb8fe468353
DOI
10.1101/2024.08.09.24311742
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Analytical Validation of a Circulating Tumor DNA Assay using PhasED-Seq Technology for Detecting Residual Disease in B-Cell MalignanciesDOI 10.1101/2024.08.09.24311742
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA.Semantic proximity
Circulating Tumor DNA as a Biomarker of Treatment Response and Minimal Residual Disease in Diffuse Large B-Cell Lymphoma: A Literature ReviewSemantic proximity
Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNASemantic proximity
The DIRECT study: A roadmap for ctDNA-based risk prediction, molecular profiling and MRD detection in Diffuse Large B Cell LymphomaSemantic proximity
Minimal Residual Disease in Oncology: From Cure to Longitudinal Patient ManagementSemantic proximity
Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphomaSemantic proximity
Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden.Semantic proximity
Circulating Tumor DNA in Lymphoma.Semantic proximity
Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma.Semantic proximity
Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational researchSemantic proximity
Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.Semantic proximity
The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas.Semantic proximity
Select a neighboring publication to make it the new centre.